Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

類似資料

• Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
  著者:: Ferrara, Roberto, 等
  出版事項: (2018)
• Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
  著者:: Auclin, Edouard, 等
  出版事項: (2021)
• Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
  著者:: Duchemann, Boris, 等
  出版事項: (2020)
• The role of brigatinib in crizotinib-resistant non-small cell lung cancer
  著者:: Mezquita, Laura, 等
  出版事項: (2018)
• Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
  著者:: Andrea De Giglio, 等
  出版事項: (2020-09-01)